NCT05951608View on ClinicalTrials.gov

A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

216

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2026

Conditions

Advanced Solid Tumors

Interventions

DRUG

AK127 in combination with AK112

AK127 in combination with AK112 (administered on Day 1 of each cycle, Q3W) up to 2 years

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Akeso

INDUSTRY